First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy
First in Human (FIH) trial results of MUVON's regenerative therapy for the treatment of stress urinary incontinence are now officially published in the International Urogynecology Journal!
Deana Mohr, CEO:
“We are thrilled with peer-review publication of our first-in-human phase I clinical trial demonstrating that the implantation of autologous muscle precursor cells for the treatment of Stress Urinary Incontinence in women is safe and feasible.”
John F Coelho, Medical Affairs:
“This tissue-engineered regenerative cell therapy was well tolerated by patients and the data was received with positive interest by the scientific community at the European Association of Urology Annual Congress in Milan.”
"We employed internationally accepted patient reported outcome measurements including ICIQ-UI-SF, the 1-hour pad test, urodynamics and MRIs at 6 months to detect changes in the urinary sphincter muscle thickness and any potential pathology."
"Our exploratory Phase II program is enrolling on schedule.”
A big thank you also to our co-authors for their efforts to bring our therapy to patients.
Florian Schmid; Jenny Prange; Marko Kozomara; Cornelia Betschart Meier; Rosa A. Sousa; Nicolas Steinke; Manuela Hunziker; Fabienne Lehner; Markus Veit; Regina Maria Grossmann; Anna Landsmann; Andreas M. Hötker; Andreas Boss; Daniel Eberli